FDA OKs Roche's Tecentriq for lung cancer patients

The Food and Drug Administration approved Roche's bladder cancer drug Tecentriq as a second-line treatment for patients with metastatic non-small cell lung cancer.

Tecentriq is an immunotherapy drug that stimulates the body's immune system to detect and attack cancer cells.

Patients with or without a tumor protein called PD-L1, which typically makes people more receptive to immunotherapy treatments, can use Tecentriq, according to Reuters.

The FDA based the approval on the results of a recent late-stage clinical trial showing patients taking Tecentriq lived, on average, 4.2 months longer than those treated with chemotherapy.

 

More articles on supply chain:

Tenn. high school opens medical device machinery lab
Sen. Blumenthal urges DOJ to reject Mylan settlement
TPC names ROi preferred supply chain partner: 3 things to know

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.